ANTI-HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) SEROPOSITIVITY IN HAEMATOLOGICAL MALIGNANCIES AT A MAJOR CLINICAL SETTING IN GHANA

10 Jul 20264 min read0 viewsVerified Feed

GIST (Key Takeaways)

Background Human T-cell lymphotropic virus - 1 (HTLV-1) is the causative agent of Adult T-cell Leukaemia/Lymphoma (ATLL), a malignancy of CD4+ cells, and HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), a demyelinating disease. Globally, 10-20 million people are infected, though most remain asymptomatic and about 5% progress to severe disease.
Transmission occurs mainly through breastfeeding, sexual contact, contaminated needles, and blood transfusion. In Ghana, evidence on the role of HTLV-1 in haematological malignancies remains scarce.
Methods This was a cross-sectional study involving 200 patients with haematological malignancies (Acute Lymphoblastic Leukaemia - 4, Acute Myeloid Leukaemia - 6, Chronic Lymphocytic Leukaemia - 27, Chronic Myeloid Leukaemia - 63, Hodgkin Lymphoma - 21, Multiple Myeloma - 31, Myelodysplasia - 6, Myeloproliferative Neoplasm - 11) at the Haematology Day Care of the Korle-Bu Teaching Hospital. After informed consent was obtained, sera from study participants were tested for anti-HTLV-1 using MP Diagnostics GmbH ELISA immunoassay.
Data were analysed using R software version 4.0.2 and SPSS version 31.0.0. Results The study population had a mean age of 49.1{+/-}17.7 years, with majority being females (n=109, 54.5%).

Clinical Editorial

medRxiv (Clinical Preprints) published a clinical update in Research Highlights on 10 Jul 2026.

The item focuses on ANTI-HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) SEROPOSITIVITY IN HAEMATOLOGICAL MALIGNANCIES AT A MAJOR CLINICAL SETTING IN GHANA.

Review the original article for the full source wording and details.